EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a lower dose of a lung cancer drug work just as well with fewer side effects?
Disease control Recruiting nowThis study tests a lower dose of the targeted therapy osimertinib in people with advanced EGFR-positive non-small cell lung cancer. The goal is to see if the lower dose can still control the cancer while causing fewer side effects. About 58 adults with specific EGFR mutations wil…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
New combo therapy offers hope for Drug-Resistant lung cancer
Disease control Recruiting nowThis study tests whether adding savolitinib to osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) that has stopped responding to osimertinib alone. The trial focuses on patients whose tumors have a low level of MET amplification. About 6…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Qingdao Central Hospital • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New program aims to ease emotional burden for advanced lung cancer patients
Symptom relief Recruiting nowThis study is testing a new supportive care program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage …
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated May 26, 2026 03:46 UTC